Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|March 4, 2015

Patheon Acquires IRIX Pharmaceuticals

Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.

 

Patheon announced on March 4 that it has reached a definitive agreement to acquire Florence, SC-based IRIX Pharmaceuticals, which specializes in difficult-to-manufacture APIs for drugs from early and late development, through commercial launch. Patheon will purchase IRIX and expects to close the transaction in 60 days.

Patheon reports that with the acquisition, it secures additional API development and manufacturing services in the United States, including high-potency (SafeBridge Class IV-certified) and controlled substances (Schedule 1-4). IRIX has facilities for the optimization of chemical processes and scale up for commercial API manufacturing in Florence and Greenville, SC.

The combined companies will offer an array of process technologies, including biocatalysis, homogeneous catalysis, and microreactors and are positioned to address a range of supply chain issues for customers, according to a press statement.

Source: Patheon


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.